Technical Analysis for NITE - The Nightview Fund NITE
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Narrow Range Bar | Range Contraction | 1.66% | |
| Down 3 Days in a Row | Weakness | 1.66% | |
| Gapped Down | Weakness | 1.66% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.50% | |
| Narrow Range Bar | Range Contraction | 0.50% | |
| Gapped Down | Weakness | 0.50% | |
| Doji - Bullish? | Reversal | 0.12% |
Free Daily (Stock) Chart Reading
The Nightview Fund NITE Description
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 2/3 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was incorporated in 2017 and is headquartered in London, the United Kingdom.
Classification
Keywords: Molecular Biology Gene Therapy Medical Genetics Retina Gene Delivery Retinal Diseases Retinitis Pigmentosa Choroideremia Stargardt Disease X Linked Retinitis Pigmentosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.03 |
| 52 Week Low | 22.55 |
| Average Volume | 2,972 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 24.28 |
| 10-Day Moving Average | 24.14 |
| Average True Range | 0.35 |
| RSI (14) | 47.37 |
| ADX | 12.94 |
| +DI | 35.93 |
| -DI | 40.13 |
| Chandelier Exit (Long, 3 ATRs) | 25.97 |
| Chandelier Exit (Short, 3 ATRs) | 23.61 |
| Upper Bollinger Bands | 26.43 |
| Lower Bollinger Band | 22.13 |
| Percent B (%b) | 0.47 |
| BandWidth | 17.68 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.61 |
| MACD Histogram | 0.0871 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.27 | ||||
| Resistance 3 (R3) | 24.27 | 24.23 | 24.25 | ||
| Resistance 2 (R2) | 24.23 | 24.20 | 24.23 | 24.24 | |
| Resistance 1 (R1) | 24.19 | 24.18 | 24.19 | 24.19 | 24.24 |
| Pivot Point | 24.15 | 24.15 | 24.15 | 24.15 | 24.15 |
| Support 1 (S1) | 24.11 | 24.12 | 24.11 | 24.11 | 24.06 |
| Support 2 (S2) | 24.07 | 24.10 | 24.07 | 24.06 | |
| Support 3 (S3) | 24.03 | 24.07 | 24.05 | ||
| Support 4 (S4) | 24.03 |
